Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for GBLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2002. Start Trial.
Date Value
December 31, 2024 -0.5064M
September 30, 2024 -0.5875M
June 30, 2024 -0.8924M
March 31, 2024 -0.9757M
December 31, 2023 -0.9431M
September 30, 2023 -1.137M
June 30, 2023 -1.340M
March 31, 2023 -1.527M
December 31, 2022 -1.972M
September 30, 2022 -2.001M
June 30, 2022 -1.522M
March 31, 2022 -1.866M
December 31, 2021 -2.133M
September 30, 2021 -2.745M
June 30, 2021 -2.498M
March 31, 2021 -2.185M
December 31, 2020 -1.485M
September 30, 2020 -2.904M
June 30, 2020 -2.172M
March 31, 2020 -4.480M
December 31, 2019 -6.256M
September 30, 2019 -5.260M
June 30, 2019 -8.991M
March 31, 2019 -9.856M
December 31, 2018 -12.07M
Date Value
September 30, 2018 -13.38M
June 30, 2018 -13.55M
March 31, 2018 -12.25M
December 31, 2017 -9.650M
September 30, 2017 -8.027M
June 30, 2017 -5.701M
March 31, 2017 -4.469M
December 31, 2016 -3.543M
September 30, 2016 -3.692M
June 30, 2016 -3.435M
March 31, 2016 -3.564M
December 31, 2015 -3.093M
September 30, 2015 -2.666M
June 30, 2015 -3.694M
March 31, 2015 -3.546M
December 31, 2014 -3.495M
September 30, 2014 -2.631M
June 30, 2014 -1.142M
March 31, 2014 -0.2136M
December 31, 2013 -0.0344M
September 30, 2013 -0.0407M
June 30, 2013 -0.0462M
March 31, 2013 -0.0374M
December 31, 2012 -0.0452M
September 30, 2012 -0.0428M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Cocrystal Pharma, Inc. -8.263M
CNBX Pharmaceuticals, Inc. -0.1542M
Arvinas, Inc. -207.00M
Fulcrum Therapeutics, Inc. -65.78M
Definium Therapeutics, Inc. -166.74M